Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1217015.RAwxSjK6Nl5nmaqrbwDfehJkAfCb-4ism-FuH_67QNbp0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1217015.RAwxSjK6Nl5nmaqrbwDfehJkAfCb-4ism-FuH_67QNbp0130_assertion type Assertion NP1217015.RAwxSjK6Nl5nmaqrbwDfehJkAfCb-4ism-FuH_67QNbp0130_head.
- NP1217015.RAwxSjK6Nl5nmaqrbwDfehJkAfCb-4ism-FuH_67QNbp0130_assertion description "[Agents targeting the JAK-STAT pathway have dominated the investigational therapeutic portfolio over the last five years resulting in the first and only approved agent for the treatment of patients with myelofibrosis (MF).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217015.RAwxSjK6Nl5nmaqrbwDfehJkAfCb-4ism-FuH_67QNbp0130_provenance.
- NP1217015.RAwxSjK6Nl5nmaqrbwDfehJkAfCb-4ism-FuH_67QNbp0130_assertion evidence source_evidence_literature NP1217015.RAwxSjK6Nl5nmaqrbwDfehJkAfCb-4ism-FuH_67QNbp0130_provenance.
- NP1217015.RAwxSjK6Nl5nmaqrbwDfehJkAfCb-4ism-FuH_67QNbp0130_assertion SIO_000772 25189730 NP1217015.RAwxSjK6Nl5nmaqrbwDfehJkAfCb-4ism-FuH_67QNbp0130_provenance.
- NP1217015.RAwxSjK6Nl5nmaqrbwDfehJkAfCb-4ism-FuH_67QNbp0130_assertion wasDerivedFrom befree-2016 NP1217015.RAwxSjK6Nl5nmaqrbwDfehJkAfCb-4ism-FuH_67QNbp0130_provenance.
- NP1217015.RAwxSjK6Nl5nmaqrbwDfehJkAfCb-4ism-FuH_67QNbp0130_assertion wasGeneratedBy ECO_0000203 NP1217015.RAwxSjK6Nl5nmaqrbwDfehJkAfCb-4ism-FuH_67QNbp0130_provenance.